Bremelanotide

(Vyleesi)

Bremelanotide

Drug updated on 12/19/2023

Dosage FormInjection (subcutaneous: 1.75 mg/0.3 mL)
Drug ClassMelanocortin receptor agonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.

Product Monograph / Prescribing Information

Document TitleYearSource
Vyleesi (bremelanotide) Prescribing Information.2021Palatin Technologies, Inc., Cranbury, NJ

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Safety profile of bremelanotide across the clinical development program.
Data not availableSubjects
F: null%
M: null%
2022Journal of Women’s Health
Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder.
1,267Subjects
F: 100%
M: 0%
2019Obstetrics & Gynecology
Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials.
1,247Subjects
F: 100%
M: 0%
2019Obstetrics & Gynecology

Sex Distribution:

NR

Year:

2022

Source:Journal of Women’s Health


Sex Distribution:

F:100%
M:0%
1267Subjects

Year:

2019

Source:Obstetrics & Gynecology


Sex Distribution:

F:100%
M:0%
1247Subjects

Year:

2019

Source:Obstetrics & Gynecology